Ocular Therapeutix (OCUL) Assets (2013 - 2026)

Ocular Therapeutix's Assets history runs 14 years deep, the most recent figure standing at $732.5 million for Q1 2026.

• On a quarterly basis, Assets rose 80.46% year-over-year to $732.5 million in Q1 2026; TTM through Mar 2026 was $732.5 million, a 80.46% increase from a year earlier, with the FY2025 full-year figure at $808.1 million, up 76.46% from the prior year.
• Assets fell to $732.5 million in Q1 2026 per OCUL's latest filing, from $808.1 million in the prior quarter.
• Across five years, Assets topped out at $808.1 million in Q4 2025 and bottomed at $122.6 million in Q2 2023.
• The 5-year median for Assets is $405.9 million (2025), against an average of $361.6 million.
• Across the five-year window, Assets plunged 31.47% in 2023 and surged 321.92% in 2024, its largest moves.
• Year by year, Assets stood at $149.3 million in 2022, then soared by 68.84% to $252.1 million in 2023, then surged by 81.68% to $457.9 million in 2024, then jumped by 76.46% to $808.1 million in 2025, then decreased by 9.35% to $732.5 million in 2026.
• Per Business Quant, the three latest OCUL Assets figures stand at $732.5 million (Q1 2026), $808.1 million (Q4 2025), and $410.9 million (Q3 2025).